Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Operating Expenses (2016 - 2025)

Lipocine's Operating Expenses history spans 13 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 32.13% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $10.6 million, down 19.55%, while the annual FY2024 figure was $12.4 million, 18.08% down from the prior year.
  • Operating Expenses reached $3.5 million in Q3 2025 per LPCN's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $4.4 million in Q1 2024 to a low of $1.9 million in Q4 2024.
  • Average Operating Expenses over 5 years is $3.2 million, with a median of $3.1 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: surged 40.3% in 2023, then plummeted 50.3% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $3.3 million in 2021, then dropped by 22.44% to $2.6 million in 2022, then grew by 9.71% to $2.8 million in 2023, then plummeted by 30.74% to $1.9 million in 2024, then skyrocketed by 78.61% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Operating Expenses are $3.5 million (Q3 2025), $3.0 million (Q2 2025), and $2.2 million (Q1 2025).